[go: up one dir, main page]

AR079059A1 - Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso - Google Patents

Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso

Info

Publication number
AR079059A1
AR079059A1 ARP100104251A ARP100104251A AR079059A1 AR 079059 A1 AR079059 A1 AR 079059A1 AR P100104251 A ARP100104251 A AR P100104251A AR P100104251 A ARP100104251 A AR P100104251A AR 079059 A1 AR079059 A1 AR 079059A1
Authority
AR
Argentina
Prior art keywords
benzazepin
oxo
carbonyl
amino
acid
Prior art date
Application number
ARP100104251A
Other languages
English (en)
Inventor
Rheenen Jeroen Van
Dasselaar Eric Eibert Van
Guido Dirk Batema
Jong Paulus Petrus Gerardus De
Touria Elhamdaoui-Achterberg
Nicolaas Buizer
Gerrit Klein
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of AR079059A1 publication Critical patent/AR079059A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica y proceso de preparacion. Reivindicacion 1: Ácido {(3S)-3-[((1-[(2R)-2-carboxi-4-(1-naftil)butil]ciclopentil}-carbonil)amino]-2-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)acético cristalino, caracterizado porque es el compuesto de formula (1). Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque tiene un espectro de difraccion de rayos X de polvo que tiene reflejos característicos (expresados en grados del ángulo de difraccion 2 theta) a: 16.32, 17.05, 20.38. Reivindicacion 4: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque tiene un espectro infrarrojo registrado en Reflectancia Total Atenuada que tiene bandas de absorcion características a 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Reivindicacion 5: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque tiene un espectro 13C-NMR en estado solido con desplazamientos característicos (expresados en ppm con relacion a glicina (delta c = 176,03 para la resonancia C=O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4, 25.9, 23.1, 21.1 +- 0.1 ppm.
ARP100104251A 2009-12-07 2010-11-18 Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso AR079059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09178226 2009-12-07

Publications (1)

Publication Number Publication Date
AR079059A1 true AR079059A1 (es) 2011-12-21

Family

ID=41682516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104251A AR079059A1 (es) 2009-12-07 2010-11-18 Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso

Country Status (3)

Country Link
AR (1) AR079059A1 (es)
TW (1) TW201127815A (es)
WO (1) WO2011069944A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
PL1706121T3 (pl) 2004-01-12 2009-02-27 Turski Lechoslaw Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors

Also Published As

Publication number Publication date
TW201127815A (en) 2011-08-16
WO2011069944A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2011060304A3 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
IL214236A0 (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
MY180672A (en) Ace2 polypeptide
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
SI1695710T1 (sl) Kristalna oblika beta-d ivabradin-hidroklorida, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
DE602007014411D1 (de) Medizinisches abgabesystem mit einem arretierungsring mit l-förmigen nuten
WO2006052968A3 (en) Stabilized ramipril compositions and methods of making
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
AR081324A1 (es) Produccion de composiciones unificadas de alta densidad
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
EA200870422A1 (ru) Улучшенное выдачное устройство
EA201070326A1 (ru) Препарат и компонент, предназначенные для добавления в табачный продукт
ZA200807024B (en) Alpha crystaline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it
CA2634695A1 (en) Assembling a packaged bundle using an adjustable multi-shelved product transporter
AR079059A1 (es) Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
NO20084942L (no) Fremgangsmate for a oke eller pavirke hyllelivet til landbruksprodukter som produserer etylen under transport og/eller lagring
MX2011007771A (es) Composiciones farmaceuticas que comprenden un profarmaco inhibidor de la polimerasa del virus de la hepatitis c (hcv).
WO2010063667A3 (en) Pharmaceutical composition comprising ezetimibe and simvastatin
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
GR1006879B (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
WO2010034825A3 (en) Novel antibodies recognizing native annexin a3
ATE536342T1 (de) Neue carbamoylglycinderivate
WO2009120378A3 (en) Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
WO2009034464A3 (en) Indole related compounds with physiological activity
WO2012034201A3 (pt) Composição de suplemento alimentar contendo creatina, processo para sua preparação e forma de dosagem de suplemento alimentar

Legal Events

Date Code Title Description
FB Suspension of granting procedure